Semantic Scholar uses AI to extract papers important to this topic.
Namitecan is a new camptothecan compound undergoing early clinical development. This study was initiated to build an… Expand SummaryPurpose: This is a first-in-human, phase I, dose-escalation study to determine the maximum tolerated dose (MTD) of… Expand Namitecan (ST1968), a novel hydrophilic camptothecin analog of the 7-oxyiminomethyl series, was selected for clinical development… Expand PurposeThe present study aimed to evaluate the new water soluble camptothecin analogue Namitecan (ST1968) in preclinical… Expand DNA damage response and checkpoint activation are expected to influence the sensitivity to DNA-damaging agents. This study was… Expand ST1968 (namitecan), a novel 7-modified hydrophilic camptothecin, was found to be effective against tumor models relatively… Expand The aim of the present study was to extend the use of the "Inverted Chirality Columns Approach (ICCA)" previously developed for… Expand ST1968 is a novel hydrophilic camptothecin (CPT) derivative of the 7-oxyiminomethyl series. Because ST1968 retained ability to… Expand ST1968, a novel hydrophilic camptothecin analogue of the 7-oxyiminomethyl series, is characterised by the formation of stable DNA… Expand In previous studies, we have documented the potential therapeutic advantages of camptothecin analogs modified at the 7-position… Expand